FDA Approves Labeling Change for Vyvanse Capsules

Shire Tuesday announced that the US Food and Drug Administration (FDA) approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment Vyvanse (lisdexamfetamine dimesylate) Capsules CII.
Benzinga